Pfiz­er's $11.6B wa­ger; TIG­IT im­plo­sion; An un­usu­al phar­ma-biotech pact; In­side a16z's vi­sion to re­shape biotech; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Are you head­ed to the BIO con­fab in San Diego next month? If so, do con­sid­er join­ing End­points for our re­turn to in-per­son pan­els since the pan­dem­ic be­gan. But don’t wor­ry if you won’t be there — we do have plen­ty of vir­tu­al pan­els lined up. Learn more here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER